Zhejiang Starry Pharmaceutical Co., Ltd.SSE: 603520

Announcement on Obtaining Drug Registration Certificate by Wholly-owned Subsidiary

· Issued by Zhejiang Starry Pharmaceutical Co., Ltd. via Shanghai Stock Exchange

Filed with SSE · · 2 pages · Chinese

Summary by 6ix AI

Zhejiang Starry Pharmaceutical Co., Ltd. announced that its wholly-owned subsidiary has received a drug registration certificate for a specific injection product from the national drug regulatory authority. The product is intended for use in magnetic resonance imaging of various body organs and tissues. This marks the second drug registration certificate obtained by the company for a contrast agent, enhancing its product pipeline. The company cautions that sales may be influenced by various market factors, leading to uncertainty regarding the impact on its performance.

Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries

Release

Announcement on Obtaining Drug Registration Certificate by Wholly-owned Subsidiary

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:

Zhejiang Starry Pharmaceutical Co., Ltd. on 6ix

Earlier from Zhejiang Starry Pharmaceutical

Later from Zhejiang Starry Pharmaceutical

All Zhejiang Starry Pharmaceutical news releases